CNS Spectrums (2014), **19**, 382–390. © Cambridge University Press 2014
doi:10.1017/S1092852914000108

ORIGINAL RESEARCH

Aggression, DRD1 polymorphism, and lesion location in penetrating traumatic brain injury

*Matteo Pardini,[1,2] Frank Krueger,[3,4] Colin A. Hodgkinson,[5] Vanessa Raymont,[6] Maren Strenziok,[4] Mario Amore,[1] Eric M. Wassermann,[7] David Goldman,[5] and Jordan H. Grafman[8]**

[1] Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, University of Genoa, Genoa, Italy
[2] Magnetic Resonance Research Centre on Nervous System Diseases, University of Genoa, Genoa, Italy
[3] Molecular Neuroscience Department, George Mason University, Fairfax, Virginia, USA
[4] Department of Psychology, George Mason University, Fairfax, Virginia, USA
[5] Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA
[6] Department of Medicine, Imperial College London, London, UK
[7] Behavioral Neurology Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
[8] Rehabilitation Institute of Chicago, Chicago, Illinois, USA

Objective. This study evaluated whether structural brain lesions modulate the relationship between pathological aggression and the dopaminergic system in traumatic brain injury (TBI). While converging evidence suggests that different areas of the prefrontal cortex modulate dopaminergic activity, to date no evidence exists of a modulation of endogenous dopaminergic tone by lesion localization in penetrating TBI (pTBI).

Methods. This study included 141 male Caucasian veterans who suffered penetrating pTBI during their service in Vietnam and 29 healthy male Caucasian Vietnam veterans. Participants were genotyped for 3 functional single nucleotide polymorphisms (SNPs): dopamine receptor D1 (*DRD1)* rs686, dopamine receptor D2 (*DRD2)* rs4648317, and catechol-O-methyltransferase (COMT) Val158Met. Patients underwent brain CT scans and were divided into medial prefrontal cortex, lateral prefrontal cortex, and posterior cortex lesion groups. Long-term aggression levels were evaluated with the agitation/aggression subscale of the Neuropsychiatric Inventory.

Results. Our data showed that carriers of more transcriptionally active *DRD1* alleles compared to noncarriers demonstrated greater aggression levels due to medial prefrontal cortex lesions but reduced aggression levels due to lateral prefrontal cortex lesions independently of *DRD2* rs4648317 or COMT Val158Met genotypes.

Conclusions. Our results suggest that the relationship between pTBI-related aggression and the dopaminergic system is modulated by lesion location. Potentially lesion location could represent an easy-to-use, widely available, paraclinical marker to help in the development of an individualized therapeutic approach to pTBI-related pathological aggression.

Received 8 December 2013; Accepted 22 January 2014; First published online 11 March 2014

Key words: Aggression, behavioral neurology, dopamine, prefrontal cortex, traumatic brain injury.

*Address for correspondence: Jordan Grafman, PhD, Director, Brain Injury Research, Coleman Chair in Physical Medicine and Rehabilitation, Rehabilitation Institute of Chicago, 345 East Superior Street, Chicago, IL 60611, USA.
(Email: jgrafman@northwestern.edu)

Authors Matteo Pardini and Frank Krueger contributed equally to this work.

The work was supported by the U.S. National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the U.S. Army Medical Research and Material Command administrated by the Henry M Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year post-injury follow-up study). The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, the Department of Defense, or the U.S. Government. M.P., F.K., and J.G. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. M.P. thanks the nonprofit association AKWO, Lavagna (Genoa) Italy, for its unrestricted support.

https://doi.org/10.1017/S1092852914000108 Published online by Cambridge University Press

Clinical Implications

- One of the unmet needs in the current approach to neuropsychiatric disturbances after penetrating traumatic brain injury is the lack of para-clinical indexes to guide individualized therapy.
- Here we showed that lesion localization modulates the relationship between aggression and the dopaminergic system, which we propose can be conceptualized as a "U" curve. Our observations seem to confirm animal and basic human neurophysiology studies, which seem to suggest that medial prefrontal lesions and lateral prefrontal lesions might respectively increase and decrease striatal dopaminergic tone.
- According to our data, lPFC lesions seem to be associated with more aggressive behaviors in subjects with a lower baseline transcriptional activity of the *DRD1* gene, while mPFC lesions seem to be associated with aggressive behaviors in subjects with a higher baseline transcriptional activity of the *DRD1* gene.

Introduction and Aim

Pathological chronic aggressive behavior has been reported in up to 33% of patients with a traumatic brain injury (TBI).[1] A number of different factors, including genetic predisposition, mono-aminergic system activity, and brain lesion location, are all thought to play a significant role in the development and maintenance of TBI-related aggression.[2] Regarding the symptomatic treatment options for aggression in TBI, to date most attention has been focused on the dopaminergic system.[3]

Despite the widespread use of anti-dopaminergic drugs to treat aggression,[4] converging evidence suggests that the relationship between dopamine and aggression is more complex than previously thought. In experimental models, for example, both D2 agonist and antagonists as well as D1 partial agonists and antagonists have been shown to reduce aggressive behaviors,[5–7] while the classic pro-dopaminergic amphetamine has been shown to increase, decrease, or fail to change aggressive behavior levels depending on various factors, such as context and type of aggression.[8]

Moreover, in humans, despite the consensus on the role of antipsychotics to treat aggression, pro-dopaminergic stimulants drugs have also been proposed as a possible pharmacological treatment for aggressive behaviors in specific patient groups. In attention deficit hyperactivity disorder (ADHD) patients, for example, stimulants have been shown to reduce aggressive behavior by remodulating to prefrontal cortex (PFC) dopamine levels,[9] while pro-dopaminergic compounds have been proposed as a possible treatment for aggressive behavior in different dementing illnesses, such as frontotemporal dementia (FTD).[10,11]

Compared to the aforementioned clinical populations, the study of the biological basis of aggressive behavior in penetrating TBI (pTBI) presents another confounding factor, ie, the presence of focal brain lesions, which could modulate the relationship between the dopaminergic system and aggression. Indeed, transcranial magnetic stimulation (TMS) experiments have shown that dorsolateral PFC inhibition reduces dopamine release in deep gray matter,[12] while dorsolateral PFC stimulation increases striatal dopaminergic activity.[13] In animal models, medial frontal lesions have been found to increase deep gray matter dopaminergic activity,[14] possibly through modulation of ventrotegmental area activity.

In this study, we explored the relationship between lesion location, pTBI-related aggressive behaviors, and dopaminergic tone. Based on the aforementioned literature and previous studies that have shown a significant role of PFC in aggressive behaviors,[2] we hypothesized that PFC lesion location significantly impacts the interaction between dopaminergic activity and aggression in pTBI. Given the key nature of PFC territories in pTBI-related aggression, we predicted a significant modulatory effect on the dopaminergic system/aggression interaction only by PFC but not non-PFC damage, and potentially a regional specificity of lesion location inside the PFC.

To test our hypotheses, we investigated, in a group of Vietnam War Veterans, the interaction between long-term pathological aggression, lesion location, and inter-individual differences in endogenous dopaminergic tone due to functional single nucleotide polymorphic (SNP) differences in the main components of the dopaminergic system,[15,16] ie, the dopamine receptor D1 (*DRD1*), the dopamine receptor D2 (*DRD2*), and the dopamine-degrading enzyme catechol-O-methyltransferase (COMT).

We decided to focus on these components of the dopaminergic system, as *DRD1* and *DRD2* represent the prototypical members of the 2 groups of dopamine receptors (ie, the *DRD1*-like and *DRD2*-like families),[15] while COMT is thought to represent the major dopamine-degrading enzyme in the synaptic cleft.[16] Evaluation of functional SNPs has been shown to be a useful tool to study the relationship between aggressive behaviors and mono-aminergic systems, both in healthy subjects and neuropsychiatric conditions,[15,16] as well as a proxy-marker of baseline dopaminergic tone in pharmacological challenges studies.[17]

Methods

Patient selection

Patients were drawn from Phase 3 of the Vietnam Head Injury Study (VHIS),[18] which was conducted

https://doi.org/10.1017/S1092852914000108 Published online by Cambridge University Press

between 2003 and 2006 (36–39 years post-injury) at the Bethesda National Naval Medical Center (Bethesda, MD, USA). Pre-injury characteristics and follow-up data of the participants (n = 189) were available from military and Veterans Administration records. Inclusion criteria were the availability of SNP data and a negative history for treatments with drugs acting on the dopaminergic or serotoninergic system and for alcohol dependence. Eight subjects were removed due to the lack of SNP data, 9 subjects due to alcohol dependence, and 2 subjects were excluded on the basis of previous pharmacological treatments. We thus included 141 Caucasian male veterans who suffered pTBI during their service in Vietnam and 29 healthy Caucasians male Vietnam veterans. Each subject underwent neurologic and psychiatric examinations, and pTBI subjects received a noncontrast brain CT scan.

Standard protocol approvals, registrations, and patient consents

All subjects gave informed written consent before enrollment in the study. The National Naval Medical Center and the National Institutes of Health (NIH) Institutional Review Boards approved all the study procedures.

Behavioral evaluation

Long-term aggression levels were evaluated with the agitation/aggression subscale of the Neuropsychiatric Inventory (NPI-a),[19] which was completed by the patients' caregivers. The NPI-a is based on a semistructured interview and grades aggressive behaviors from 0 to 12, with higher values indicating more severe levels of aggression. The NPI-a has been used in clinical studies on aggression in brain injury[2] and other neurological conditions.[19] Moreover, we also used the total NPI (NPI-t) score as a global index of psychopathology. Last, we evaluated early psychological trauma by administering the Early Trauma Inventory (ETI), a validated 56-item interview that was designed for the assessment of childhood negative experiences.[20]

Computed tomography (CT) scans

Axial noncontrast CT scans were acquired on a GE Medical Systems Light Speed Plus CT-scanner in helical mode as described elsewhere.[18] Briefly, images were reconstructed with an in-plane voxel size of 0.4 mm × 0.4 mm, overlapping slice thickness of 2.5 mm, and a 1-mm slice interval. Lesion location and volume were determined from CT images by manual tracing using the Analysis of Brain Lesion (ABLe)[21] software implemented in MEDx v3.44 (Medical Numerics) with enhancements to support the Automated Anatomical Labeling (AAL) atlas.[22] A trained neuropsychiatrist (V.R.) performed the tracings, which were then reviewed by an experienced observer (J.G.) who was blind to the results of the clinical evaluations. The skull and scalp were then removed from the CT images; each volume was spatially normalized to a de-skulled CT scan, which was previously spatially normalized to the T1 MNI brain (standard of the International Consortium for Brain Mapping). The ABLe software was used to exclude the manually delineated lesion from the spatial normalization process to improve registration accuracy. Spatial normalization was performed using an automated image registration algorithm using a 12-parameter affine model. The medial PFC (mPFC) region of interest was defined as those areas of the PFC medial to $x = -20$ and to $x = 20$ in the Montreal Neurological Institute (MNI) space as previously described.[23] Subjects with a PFC lesion encompassing or partially encompassing the mPFC were included in the "mPFC group," while all other subjects with PFC lesions were included in the "lateral PFC (lPFC) group." Subjects with non-PFC lesions were included in the "non-PFC group."

Differences in lesion localization among the 3 groups are reported in Figure 1 using lesion subtraction maps that have been previously used in pTBI research to characterize differences in lesion localization among groups.[2]

Genetic analysis

From a published SNP array,[24] we selected the following functional SNPs: *DRD1* rs686 (A-to-G), *DRD2* rs4648317 (C-to-T), and COMT Val158Met rs4680 (G-to-A). Rs686 is a functional SNP located in the promoter region of the *DRD1* gene; its A allele is linked with increased transcriptional activity compared to the G allele.[25] Rs4274224 is located in the first intronic region of the DRD2 gene; the minor allele has been linked with reduced D2 expression in healthy controls compared to the major allele.[26] Moreover, this SNP has been shown to impact behavioral inhibition.[27] COMT Val158Met rs4680 is a widely studied SNP in neuropsychiatry, and the Val allele is thought to be linked with a reduced efficiency in the degradation of dopamine.[16] Last, we decided to control for possible differences among subjects for the monoamine oxidase A (MAO-A) genotype, one of the genes more commonly linked to pathological aggression.[2,28] While the main role of the MAO-A is serotonin metabolism rather than dopamine, we decided to include it as a confounding factor since the common variable number tandem repeat (VNTR) polymorphism is known to impact aggression levels in the general population.[28] VNTR MAO-A polymorphisms are thought to modulate MAO-A activity with the 3.5 and 4 repeats linked with MAO-A

https://doi.org/10.1017/S1092852914000108 Published online by Cambridge University Press




FIGURE 1. Subtraction lesions maps for the mPFC group (red), lPFC group (green), and non-PFC group (blue). For each group, the subtraction lesion map shows those brain areas that were more lesioned in 1 group compared to the other groups. Note that each subject was only included in 1 group.

high-activity and 2, 3, and 5 repeats linked with low MAO-A activity. Genotyping for the those SNPs was performed as described elsewhere.[2,18,24]

Statistical analysis

Statistical threshold was set at 0.05 (2-tailed) for all first-level analyses. For each of our target SNPs (*DRD1* rs686, *DRD2* rs4648317, and COMT Val158Met rs4680), a mixed 2×4 analysis of covariance (ANCOVA) on NPI-a (and NPI-t as a control measure) was performed with Genotype (major allele/–, minor allele/minor allele) and Group (mPFC, lPFC, non-PFC, control) as between-subjects factors and the other target genes as covariates. Based on our DRD1 results (see below), we also performed a 2×4 ANCOVA on NPI-a scores (and NPI-t scores) with *DRD1* Genotype and Group as between-subjects factors and *DRD2*, COMT, and MAO VNTR genotype as covariates. Follow-up independent t-tests (Bonferroni corrected for multiple comparisons) were performed for the rs686 genotypes within each lesion group.

Results

Group characteristics

All four groups did not present with significant differences in pre-injury intelligence ($F_{(3,165)} = 1.2$, $p = 0.31$), early life negative experiences ($F_{(3,165)} = 0.7$, $p = 0.55$), education level ($F_{(3,165)} = 0.8$, $p = 0.50$), and age ($F_{(3,165)} = 0.4$, $p = 0.75$), and the lesion groups were matched on percentage of brain tissue loss due to pTBI ($F_{(2,137)} = 0.9$, $p = 0.41$) (Table 1). Lesion subtraction maps are reported in Figure 1. Frequency distributions for the genotyping results were as follows: *DRD1*: 97 A/– vs 73 G/G subjects; *DRD2*: 117 C/– vs C/– subjects vs 53 T/T; COMT: 107 Val/– vs 63 Met/Met subjects; MAO-A: 59 low-activity vs 111 high-activity subjects.

DRD1

The ANCOVA on NPI-a revealed a significant interaction effect for *DRD1* Genotype × Group ($F_{(3,159)} = 9.5$, $p = 0.001$), but no significant main effects were found for *DRD1* Genotype ($F_{(1,159)} = 0.4$, $p = 0.58$) and Group ($F_{(3,159)} = 1.2$, $p = 0.35$) and no covariate effect was found for COMT ($F_{(1,159)} = 0.45$, $p = 0.55$), DRD2 ($F_{(1,159)} = 0.60$, $p = 0.4$) or MAO-A ($F_{(1,159)} = 0.35$, $p = 0.35$). Planned follow-up analyses showed that *DRD1* A/– carriers had higher NPI-a scores than G/G carriers in the mPFC group ($t = 2.99$, $p = 0.004$; Cohen's $d = 1.9$), whereas *DRD1* A/– carriers had lower NPI-a scores than G/G carriers in the lPFC group ($t = 3.82$, $p = 0.002$; Cohen's $d = 1.89$) (Figure 2). No significant differences were found between genotypes in the non-PFC ($t = 0.92$, $p = 0.36$) and control ($t = 0.72$, $p = 0.48$) groups.

The ANCOVA on NPI-t revealed no significant main effects (*DRD1* Genotype: $F_{(1,159)} = 1.5$, $p = 0.25$; Group: $F_{(3,159)} = 0.85$, $p = 0.38$); interaction effect ($F_{(3,159)} = 1.1$, $p = 0.37$); or COMT, *DRD2*, and MAO-A covariate effects.

https://doi.org/10.1017/S1092852914000108 Published online by Cambridge University Press

TABLE 1. Demographic and clinical data for the experimental DRD1 rs686 groups

DRD1 rs686 group	NPI-a	NPI-t	Pre-injury IQ	Age	Education	% of brain volume loss	ETI
				mPFC lesion group			
A/– (n = 22)	2.70 ± 0.2	5.6 ± 0.8	59.5 ± 4.6	57.5 ± 0.4	14.6 ± 0.4	3.2 ± 0.4	5.6 ± 0.4
G/G (n = 34)	0.52 ± 0.2	5.1 ± 0.7	58.0 ± 4.2	58.8 ± 0.4	14.3 ± 0.3	3.4 ± 0.4	5.9 ± 0.3
				lPFC lesion group			
A/– (n = 20)	0.46 ± 0.2	5.2 ± 0.7	58.5 ± 5.6	58.8 ± 0.3	14.3 ± 0.4	4.0 ± 0.6	5.5 ± 0.5
G/G (n = 31)	2.40 ± 0.3	5.6 ± 0.9	59.6 ± 4.1	58.2 ± 0.5	15.0 ± 0.5	3.9 ± 0.7	5.8 ± 0.3
				Non-PFC lesion group			
A/– (n = 14)	1.22 ± 0.3	5.6 ± 0.8	63.7 ± 5.8	58.2 ± 0.3	14.8 ± 0.4	3.0 ± 0.3	6.0 ± 0.5
G/G (n = 20)	1.44 ± 0.2	5.4 ± 0.8	62.2 ± 6.0	58.6 ± 0.5	14.9 ± 0.5	3.2 ± 0.4	5.9 ± 0.6
				Control group			
A/– (n = 10)	0.93 ± 0.4	5.4 ± 0.6	60.2 ± 8.6	58.2 ± 0.6	15.4 ± 0.8	N/A	6.0 ± 0.4
G/G (n = 19)	1.12 ± 0.2	4.9 ± 0.5	61.2 ± 9.4	59.1 ± 0.3	15.5 ± 0.6	N/A	5.9 ± 0.5

Note: NPI-a: Neuropsychiatric Inventory Aggression sub-score; NPI-t: Neuropsychiatric Inventory Total score; ETI: Early Trauma Inventory Score.




FIGURE 2. NPI-a scores (mean ± s.e.m.) for the lesion groups divided according to the functional SNP DRD1 rs686. *Indicates a significant difference between the 2 genotype groups at $p < 0.05$ (Bonferroni correction).

https://doi.org/10.1017/S1092852914000108 Published online by Cambridge University Press

DRD2

The *DRD2* × Group ANCOVA performed on NPI-a scores revealed no significant main effects (*DRD2* genotype: $F_{(1,159)} = 1.7$, $p = 0.52$; Group: $F_{(3,159)} = 0.5$, $p = 0.80$); interaction effect ($F_{(3,159)} = 0.15$, $p = 0.92$); or *DRD1*, COMT, and MAO-A covariate effects.

COMT

The COMT Genotype × Group ANCOVA performed on NPI-a scores revealed no significant main effects (COMT genotype: $F_{(1,159)} = 0.7$, $p = 0.40$; Group: $F_{(3,159)} = 0.2$, $p = 0.89$); interaction effect ($F_{(3,159)} = 0.15$, $p = 0.92$); or *DRD1*, *DRD2*, and MAO-A covariate effects.

Discussion

In this study, we studied the relationship between TBI-related aggression and the dopaminergic system and its modulation by lesion location. Our results revealed a significant interaction between aggressive behavior and the *DRD1* rs686 SNP depending upon PFC lesion location. We showed that carriers of the major and more transcriptionally active allele of *DRD1* were more aggressive compared to the minor allele homozygotes in the mPFC group, while conversely, *DRD1* major allele carriers were less aggressive than minor allele homozygotes in the lPFC group.

Moreover, we did not observe any significant interactions between lesion location and genotype for *DRD2* or COMT functional SNPs, thus suggesting a possible specificity of this effect to *DRD1* receptors. Last, no genotype effects were observed in the non-PFC and control groups or when taking into account the global index of psychopathology.

We propose that our observation of high aggression levels in 2 specific subsets of pTBI patients—(1) subjects with mPFC lesions and more expressed DRD1 receptors and (2) subjects with lPFC lesions and less expressed DRD1 receptors—can be explained by analogy to the known relationship between impaired cognitive performance and excessively high or low levels of dopamine (ie, the observed ''U-curve'' relationship between cognitive performance and dopaminergic tone).[29]

While the ''U-shaped curve'' relationship between function and dopamine levels was first observed at the neural level, recent years have seen its generalization to the behavioral, whole-organism setting. In rats, for example, both D1 agonists and antagonists have been shown to impair working memory performance in a dose-dependent function, leading to a U-shaped curve–like relationship (ie, rats presented an equally pathological performance both during excessive inhibition and excessive stimulation of the D1 receptors).[30] Moreover, in line with the proposed U-shaped curve relationship between dopamine tone and performance, a *DRD2* agonist, cabergoline, increased neural reward responses during a feedback-based reversal learning fMRI task in healthy subjects with low *DRD2* receptor density due to the A1+ Taq1A SNP, while it reduced reward responses in those subjects with higher *DRD2* receptor density due to the A– Taq1A SNP.[17] Last, a dopamine agonist, bromocriptine, has been shown to increase cognitive performance in healthy subjects with lower baseline dopamine synthesis–as quantified with fluoro-L-m-tyrosine PET scans, but showed an opposite effect (ie, a performance reduction) in subjects with higher baseline dopaminergic tone.[31]

Our findings suggest that subjects with lPFC lesions and less expressed *DRD1* represent the other extreme of the proposed ''U-shaped curve'' relationship between dopaminergic tone and aggression (ie, association of high levels of aggression with reduced D1 signaling). This proposal is in line with the observed reduction of deep brain dopaminergic activity in lPFC virtual-lesion studies based on theta-burst TMS[13] and an increased striatal dopaminergic tone after lPFC activation.[14]

Thus, the combination of reduced dopaminergic activity with low *DRD1* expression could lead to low D1 tone in different subcortical areas linked with aggression, such as the nucleus accumbens (NA). According to pharmaco-fMRI studies, low D1 activity is linked with blunted NA responses to environmental stimuli.[32] A similar blunted NA response to environmental stimuli has been shown in subjects with ADHD, and it has been correlated with the extent of externalizing symptoms, which include aggressive conduct.[33] Interestingly, pro-dopaminergic stimulants are widely used to control externalizing aggressive behaviors in ADHD,[9] as well as in some experimental models of aggression.[34] Last, a relationship between NA neurodegeneration and disinhibited behavior has been shown in FTD in which pro-dopaminergic stimulants are used to treat aggression.[35]

Our findings also indicate that subjects with mPFC lesions and more expressed *DRD1* represent the ''high dopamine'' end of the proposed ''U-shaped curve.'' The mPFC territories are richly interconnected with the ventrotegmental area (the origin of the mesolimbic dopaminergic pathway to the NA), which suggests a modulatory effect of mPFC on the dopaminergic system,[36] as shown in animal lesion models in which the structural lesion of medial PFC territories was linked with an increase in NA dopaminergic activity.[15] These observations are in line with the observed activation by mPFC projections of inhibitory GABA-ergic interneurons in the dopaminergic mesolimbic pathway,[36] as well as with the reported inverse correlation between mPFC and NA activity during immediate reward evaluation

https://doi.org/10.1017/S1092852914000108 Published online by Cambridge University Press

in impulsive subjects.[37] Given the relationship between D1 signaling and NA activity, the presence of mPFC lesions in subjects with highly expressed DRD1 could lead to an excessively active NA, especially in behaviorally relevant impulsive decision-making settings, and possibly to heightened aggressive behaviors.[38]

We propose that our finding of high aggression levels in pTBI subjects with mPFC lesions and more expressed *DRD1* and in subjects with lPFC lesions and less expressed *DRD1* supports a U-shaped curve modulation of the function of the mesolimbic dopaminergic system. Coincidentally, in a recent meta-analysis of striatal activation during reward anticipation tasks, a similar U-shaped curve paradigm has been proposed to link the reduced reward responsiveness of mesolimbic striatal structures observed in subjects with extremely high or extremely low impulsivity observed in ADHD and healthy control group.[39] Our findings have a potential translational application in the pharmacological treatment of behavioral disturbances in pTBI patients.[40] Lesion location could represent a low-cost, easy-to-use, para-clinical marker to help, among other factors, in the development of individualized treatment protocols.

Indeed, our findings seem to suggest that in subjects with isolated lPFC lesions D1-agonists could represent the treatment of choice for aggressive behaviors, while the compounds in this class should be avoided in subjects with isolated mPFC lesions.

Albeit indirectly, moreover, our data also advise prudence in the use of D1-active drugs in subjects with mixed mPFC/lPFC, even if our study did not directly investigate this patient group. However, while this proof-of-concept study suggests the importance of a personalized approach to aggression treatment in pTBI, future studies are needed to explore its relevance in day-to-day clinical care.

Interestingly (but unexpectedly), given the widespread use of D2-antagonists to treat behavioral disturbances in pTBI,[41] we did not find any effect of the DRD2 SNP on aggression in our target populations. We argue that this observation, while it needs to be interpreted with caution, is in line with the growing evidence of the difficulties in generalizing findings from general psychiatry to neuropsychiatry. Indeed, different studies showed that chronic reduction of D2 tone using *DRD2* inhibitors after TBIs increases the risk of stable cognitive deficits,[42,43] which, given the relationship between cognitive deficits and behavioral disturbances in pTBI, could counter the potentially positive effect of D2 inhibition on aggressive behaviors in this population.

One of the key aspects of our study is the composition of our patient group. Our experimental group is highly homogeneous regarding pTBI (all subjects suffered combat-related pTBI during their service in Vietnam), their demographic characteristics (all subjects suffered pTBI during their early adulthood), and their pre-injury cognitive levels. Moreover, all subjects were matched for their early negative experience burden and their exposure to aggressive environments (ie, all of them were exposed to infantry warfare and suffered a major injury). While this homogeneity allowed us to control for possible confounding factors (eg, pre-injury characteristics, TBI dynamics, and exposure to significant aggressive behaviors), it also represents the main limitation of this study, which prompts the need to also evaluate our findings in non-military heterogeneous populations. Another limitation of this study is the lack of anatomical information on pTBI-related white matter damage, since retained metal fragments in the brain preclude high resolution structural MRI studies.

Moreover, in this study we focused on *DRD1* and *DRD2*, as they represent the prototypical members of the 2 families of dopamine receptors (ie, the *DRD1*-like and the *DRD2*-like families).[15] Future studies, however, are warranted to explore the role of other dopaminergic receptors in behavioral disturbances in pTBI, especially taking into account the differences in the anatomical localization of the different receptors. *DRD4*, for example, seems to be of particular interest, as it is widely expressed in the PFC[44] and been associated with inter-individual differences in externalizing behaviors,[45] as well as with resilience after negative life experiences.[46]

The longitudinal aspect of our study allowed us to evaluate the behavioral consequences of pTBI across the patients' lifetime, which are a major determinant of quality of life levels both for our patients and their caregivers. Furthermore, the length of our follow-up suggests caution in the interpretation of our data, especially regarding their generalizability to the acute and sub-acute settings.

Conclusions

Our results suggest that pTBI modulates the relationship between pTBI-related aggression and the dopaminergic system in a lesion-location dependent way; potentially, lesion location could help in the development of individualized therapies for treatment-resistant aggression, for example, suggesting prudence in the use of D1-antagonists in subjects with lPFC lesions or of D1-agonists in subjects with mPFC damage. Pharmacological studies are warranted to explore the translational relevance of our findings.

Disclosures

Dr. Pardini received an educational grant from the nonprofit association AKWO, Lavagna (Genoa, Italy). Dr. Krueger, Dr. Hodgkinson, Dr. Raymont,

https://doi.org/10.1017/S1092852914000108 Published online by Cambridge University Press

Dr. Strenziok, Dr. Wassermann, and Dr. Amore report no disclosures. Dr. Goldman serves on the editorial boards of *Biological Psychiatry* and *Addictions Biology*. Dr. Grafman was supported by the U.S. National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the U.S. Army Medical Research and Material Command administrated by the Henry M Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year post-injury follow-up study) and serves as co-editor of *Cortex*.

REFERENCES:

1. Tateno A, Jorge RE, Robinson RG. Clinical correlates of aggressive behavior after traumatic brain injury. *J Neuropsychiatry Clin Neurosci*. 2003; **15**(2): 155–160.
2. Pardini M, Krueger F, Hodgkinson C, *et al*. Prefrontal cortex lesions and MAO-A modulate aggression in penetrating traumatic brain injury. *Neurology*. 2011; **76**(12): 1038–1045.
3. Comai S, Tau M, Gobbi G. The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology. *J Clin Psychopharmacol*. 2012; **32**(1): 83–94.
4. Goedhard LE, Stolker JJ, Heerdink ER, *et al*. Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: a systematic review. *J Clin Psychiatry*. 2006; **67**(7): 1013–1024.
5. Tidey JW, Miczek KA. Effects of SKF 38393 and quinpirole on aggressive, motor and schedule-controlled behaviors in mice. *Behav Pharmacol*. 1992; **3**(6): 553–565.
6. Rodríguez-Arias M, Miñarro J, Aguilar MA, Pinazo J, Simón VM. Effects of risperidone and SCH 23390 on isolation-induced aggression in male mice. *Eur Neuropsychopharmacol*. 1998; **8**(2): 95–103.
7. Aguilar MA, Miñarro J, Pérez-Iranzo N, Simón VM. Behavioral profile of raclopride in agonistic encounters between male mice. *Pharmacol Biochem Behav*. 1994; **47**(3): 753–756.
8. Miczek KA, Tidey JW. Amphetamines: aggressive and social behavior. In: Asghar K, De Souza E, eds. *Pharmacology and Toxicology of Amphetamine and Related Designer Drugs*. Washington, DC: National Institute on Drug Abuse; 1989: 68Y100.
9. Blader JC, Pliszka SR, Jensen PS, Schooler NR, Kafantaris V. Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. *Pediatrics*. 2010; **126**(4): 796–806.
10. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. *Neurology*. 2006; **66**(1): 17–22.
11. Huey ED, Garcia C, Wassermann EM, Tierney MC, Grafman J. Stimulant treatment of frontotemporal dementia in 8 patients. *J Clin Psychiatry*. 2008; **69**(12): 1981–1982.
12. Ko JH, Monchi O, Ptito A, *et al*. Theta burst stimulation-induced inhibition of dorsolateral prefrontal cortex reveals hemispheric asymmetry in striatal dopamine release during a set-shifting task: a TMS-[(11)C]raclopride PET study. *Eur J Neurosci*. 2008; **28**(10): 2147–2155.
13. Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. *J Neurosci*. 2001; **21**(15): RC157.
14. Jaskiw GE, Karoum FK, Weinberger DR. Persistent elevations in dopamine and its metabolites in the nucleus accumbens after mild subchronic stress in rats with ibotenic acid lesions of the medial prefrontal cortex. *Brain Res*. 1990; **534**(1-2): 321–323.
15. Seeman P, Van Tol HH. Dopamine receptor pharmacology. *Trends Pharmacol Sci*. 1994; **15**(7): 264–270.
16. Volavka J, Bilder R, Nolan K. Catecholamines and aggression: the role of COMT and MAO polymorphisms. *Ann N Y Acad Sci*. 2004; **1036**: 393–398.
17. Cohen MX, Krohn-Grimberghe A, Elger CE, Weber B. Dopamine gene predicts the brain's response to dopaminergic drug. *Eur J Neurosci*. 2007; **26**(12): 3652–3660.
18. Raymont V, Greathouse A, Reding K, *et al*. Demographic, structural and genetic predictors of late cognitive decline after penetrating head injury. *Brain*. 2008; **131**(Pt 2): 543–558.
19. Cummings JL, Mega M, Gray K, *et al*. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. *Neurology*. 1994; **44**(12): 2308–2314.
20. Bremner JD, Vermetten E, Mazure CM. Development and preliminary psychometric properties of an instrument for the measurement of childhood trauma: the Early Trauma Inventory. *Depress Anxiety*. 2000; **12**(1): 1–12.
21. Solomon J, Raymont V, Braun A, Butman JA, Grafman J. User-friendly software for the analysis of brain lesions (ABLe). *Comput Methods Programs Biomed*. 2007; **86**(3): 245–254.
22. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, *et al*. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage*. 2002; **15**(1): 273–289.
23. Koenigs M, Huey ED, Calamia M, Raymont V, Tranel D, Grafman J. Distinct regions of prefrontal cortex mediate resistance and vulnerability to depression. *J Neurosci*. 2008; **28**(47): 12341–12348.
24. Hodgkinson CA, Yuan Q, Xu K, *et al*. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. *Alcohol Alcohol*. 2008; **43**(5): 505–515.
25. Huang W, Ma JZ, Payne TJ, *et al*. Significant association of DRD1 with nicotine dependence. *Hum Genet*. 2008; **123**(2): 133–140.
26. Fukui N, Suzuki Y, Sugai T, *et al*. Exploring functional polymorphisms in the dopamine receptor D2 gene using prolactin concentration in healthy subjects. *Mol Psychiatry*. 2010; **16**(4): 356–358.
27. Hamidovic A, Dlugos A, Skol A, Palmer AA, de Wit H. Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants. *Exp Clin Psychopharmacol*. 2009; **17**(6): 374–383.
28. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. *Annu Rev Neurosci*. 1999; **22**(1): 197–217.
29. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. *Nat Neurosci*. 2007; **10**(3): 376–384.
30. Floresco SB. Prefrontal dopamine and behavioral flexibility: shifting from an ''inverted-U'' toward a family of functions. *Front Neurosci*. 2013; **7**: 62.
31. Cools R, Frank MJ, Gibbs SE, *et al*. Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. *J Neurosci*. 2009; **29**(5): 1538–1543.
32. Knutson B, Gibbs SE. Linking nucleus accumbens dopamine and blood oxygenation. *Psychopharmacology (Berl)*. 2007; **191**(3): 813–822.
33. Scheres A, Milham MP, Knutson B, Castellanos FX. Ventral striatal hyporesponsiveness during reward anticipation in attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2007; **61**(5): 720–724.
34. Couppis MH, Kennedy CH. The rewarding effect of aggression is reduced by nucleus accumbens dopamine receptor antagonism in mice. *Psychopharmacology (Berl)*. 2008; **197**(3): 449–456.
35. Zamboni G, Huey ED, Krueger F, Nichelli PF, Grafman J. Apathy and disinhibition in frontotemporal dementia: insights into their neural correlates. *Neurology*. 2008; **71**(10): 736–742.

https://doi.org/10.1017/S1092852914000108 Published online by Cambridge University Press

36. Takahata R, Moghaddam B. Target-specific glutamatergic regulation of dopamine neurons in the ventral tegmental area. *J Neurochem*. 2000; **75**(4): 1775–1778.
37. Diekhof EK, Nerenberg L, Falkai P, *et al*. Impulsive personality and the ability to resist immediate reward: an fMRI study examining interindividual differences in the neural mechanisms underlying self-control. *Hum Brain Mapp*. 2012; **33**(12): 2768–2784.
38. Buckholtz JW, Treadway MT, Cowan RL, *et al*. Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. *Nat Neurosci*. 2010; **13**(4): 419–421.
39. Plichta MM, Scheres A. Ventral-striatal responsiveness during reward anticipation in ADHD and its relation to trait impulsivity in the healthy population: a meta-analytic review of the fMRI literature. *Neurosci Biobehav Rev*. 2014; **38**: 125–134.
40. Wong TM. Brain injury and aggression: can we get some help? *Neurology*. 2011; **76**(12): 1032–1033.
41. Fowler SB, Hertzog J, Wagner BK. Pharmacological interventions for agitation in head-injured patients in the acute care setting. *J Neurosci Nurs*. 1995; **27**(2): 119–123.
42. Kline AE, Massucci JL, Zafonte RD, *et al*. Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental brain trauma. *Crit Care Med*. 2007; **35**(3): 919–924.
43. Hoffman AN, Cheng JP, Zafonte RD, Kline AE. Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits. *Life Sci*. 2008; **83**(17–18): 602–607.
44. de Almeida J, Palacios JM, Mengod G. Distribution of 5-HT and DA receptors in primate prefrontal cortex: implications for pathophysiology and treatment. *Prog Brain Res*. 2008; **172**: 101–115.
45. DeYoung CG, Peterson JB, Séguin JR, *et al*. The dopamine D4 receptor gene and moderation of the association between externalizing behavior and IQ. *Arch Gen Psychiatry*. 2006; **63**(12): 1410–1416.
46. Bakermans-Kranenburg MJ, van Ijzendoorn MH, Caspers K, Philibert R. DRD4 genotype moderates the impact of parental problems on unresolved loss or trauma. *Attach Hum Dev*. 2011; **13**(3): 253–269.

https://doi.org/10.1017/S1092852914000108 Published online by Cambridge University Press